Satyam Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 12-07-2024
- Paid Up Capital ₹ 2.43 M
as on 12-07-2024
- Company Age 24 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.08 Cr
as on 12-07-2024
- Revenue 100.47%
(FY 2020)
- Profit 125.24%
(FY 2020)
- Ebitda 513.64%
(FY 2020)
- Net Worth 0.22%
(FY 2020)
- Total Assets -0.66%
(FY 2020)
About Satyam Biotech
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.43 M.
The company currently has active open charges totaling ₹3.08 Cr.
Nitu Bondia and Jagdish Bondia serve as directors at the Company.
- CIN/LLPIN
U24239OR2000PTC006219
- Company No.
006219
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 May 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- LocationJharsuguda, Orissa
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Satyam Biotech Private Limited offer?
Satyam Biotech Private Limited offers a wide range of products and services, including Gate, Grilles, Fences & Railings, Fencing Materials, Building Panels & Cladding Materials, Building & Electricity Poles, Drainage Pipes & Pipe Fittings, RCC Hume Pipes.
Who are the key members and board of directors at Satyam Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagdish Bondia  | Managing Director | 12-May-2000 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nitu Bondia | Director | 17-Dec-2014 | Current |
Financial Performance of Satyam Biotech.
Satyam Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 100.47% increase. The company also saw a substantial improvement in profitability, with a 125.24% increase in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satyam Biotech?
In 2019, Satyam Biotech had a promoter holding of 20.86% and a public holding of 79.14%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
United Bank Of India Creation Date: 07 May 2007 | ₹3.08 Cr | Open |
How Many Employees Work at Satyam Biotech?
Unlock and access historical data on people associated with Satyam Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satyam Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satyam Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
